BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1826 related articles for article (PubMed ID: 21135382)

  • 1. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
    Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
    Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
    Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
    Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
    Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
    PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
    Cysique LA; Brew BJ
    J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.
    Heaton RK; Franklin DR; Ellis RJ; McCutchan JA; Letendre SL; Leblanc S; Corkran SH; Duarte NA; Clifford DB; Woods SP; Collier AC; Marra CM; Morgello S; Mindt MR; Taylor MJ; Marcotte TD; Atkinson JH; Wolfson T; Gelman BB; McArthur JC; Simpson DM; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I; ;
    J Neurovirol; 2011 Feb; 17(1):3-16. PubMed ID: 21174240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
    Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
    AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
    van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
    AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
    Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
    J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psycho-behavioral factors associated with neurocognitive performance among people living with HIV on antiretroviral therapy in Accra, Ghana.
    Asiedu N; Kretchy I; Asampong E
    Afr Health Sci; 2020 Jun; 20(2):487-596. PubMed ID: 33163015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.
    Kallianpur AR; Wang Q; Jia P; Hulgan T; Zhao Z; Letendre SL; Ellis RJ; Heaton RK; Franklin DR; Barnholtz-Sloan J; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Grant I;
    J Infect Dis; 2016 Apr; 213(7):1065-73. PubMed ID: 26690344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
    Cysique LA; Vaida F; Letendre S; Gibson S; Cherner M; Woods SP; McCutchan JA; Heaton RK; Ellis RJ
    Neurology; 2009 Aug; 73(5):342-8. PubMed ID: 19474412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.
    Evering TH; Applebaum A; La Mar M; Garmon D; Dorfman D; Markowitz M
    AIDS; 2016 Jan; 30(2):203-10. PubMed ID: 26684817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS.
    Tymchuk S; Gomez D; Koenig N; Gill MJ; Fujiwara E; Power C
    Can J Psychiatry; 2018 May; 63(5):329-336. PubMed ID: 29228820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and 1-year incidence of HIV-associated neurocognitive disorder (HAND) in adults aged ≥50 years attending standard HIV clinical care in Kilimanjaro, Tanzania.
    Flatt A; Gentry T; Kellett-Wright J; Eaton P; Joseph M; Urasa S; Howlett W; Dekker M; Kisoli A; Rogathe J; Henderson L; Lewis T; Thornton J; McCartney J; Yarwood V; Irwin C; Mukaetova-Ladinska EB; Akinyemi R; Gray WK; Walker RW; Dotchin CL; Quaker AS; Makupa PC; Paddick SM
    Int Psychogeriatr; 2023 Jul; 35(7):339-350. PubMed ID: 33757616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.
    Cysique LA; Brew BJ
    Neuropsychol Rev; 2009 Jun; 19(2):169-85. PubMed ID: 19424802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.
    Nichols SL; Bethel J; Garvie PA; Patton DE; Thornton S; Kapogiannis BG; Ren W; Major-Wilson H; Puga A; Woods SP
    J Adolesc Health; 2013 Dec; 53(6):763-71. PubMed ID: 23972941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive Disorders in HIV-positive Patients.
    Padole PS; Padhiyar RN; Yadav DS; Chavan SA
    J Assoc Physicians India; 2023 Jun; 71(6):11-12. PubMed ID: 37355842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.